Icon PLC

Icon reported revenue of $2.06 billion in the second quarter, up 1.2% from the prior-year period. Net business wins in the quarter were $3.1 billion, and the backlog increased 3% sequentially to $23.4 billion. Management maintained its 2026 guidance, including revenue of $8 billion at the midpoint.

Why it matters: While near-term financial performance remains constrained by mix-related margin pressure from elevated pass-through activity, we see positive signs, driven by improving biotech funding levels and better win rates in large pharma. We are encouraged by Icon's larger proposal values and increasing exposure to phase 3 trials, which accounted for roughly 50% of opportunity volume in the quarter, up from about 40% a year ago. We believe this shift toward later-stage development programs should support higher-quality backlogs, improved revenue visibility, and a clearer path to maintainable growth. We view Icon's direct-fee book/bill ratio of 1.2 times as the better indicator of Icon's solid underlying business momentum, suggesting that recent bookings strength reflects genuine commercial improvement rather than the pass-through-heavy awards that inflate its headline net book/bill ratio of 1.5 times.

The bottom line: We maintain our $155 fair value estimate for no-moat Icon. Shares are trading slightly above our fair value estimate in 3-star territory. We forecast roughly $8 billion in 2026 revenue, representing a 3% year-over-year decline, partially driven by headwinds from the divestiture of Symphony Health and the lingering drag of weak bookings in 2024 and 2025 on organic growth. While Icon has been navigating mix headwinds in the first half of this year, management's cost actions and improving business mix should support improved profitability. We forecast 2026 adjusted diluted earnings per share of $10.50, which still would be down from $12.53 in 2025.

BLANK PAGE

We maintain Icon's fair value estimate of $155 per share.

Our near-term low-single-digit sales forecast is driven less by the mechanical revenue correction from Icon's accounting investigation and more by second-order effects, such as competitive pressure, slower bookings in 2024 and 2025, reputational risks, and internal control concerns, which support our downgrade to a no-moat rating. If Icon faces market share pressure, it will need to offer discounts to win future business and accept lower-margin contracts, which would reduce growth over the next several years.

We anticipate elevated near-term costs associated with the accounting investigation will result in lower near-term operating margins, but we expect margins to gradually increase as the company leverages fixed costs over a larger revenue base.

While near-term financial performance remains constrained by mix-related margin pressure from elevated pass-through activity, we see positive signs, driven by improving biotech funding levels and higher win rates in large pharma. Icon has been working through a challenging macroeconomic environment, as some of its customers were undergoing budget cuts and reprioritizations of their pipeline candidates. Management remains focused on driving operational utilization and cost control measures.

We are encouraged by Icon's higher proposal values and increasing exposure to phase 3 trials, which accounted for roughly 50% of opportunity volume in the second quarter, up from about 40% a year ago. We believe this shift toward later-stage development programs should support higher-quality backlogs, improved revenue visibility, and a clearer path back to sustainable growth.

We anticipate outsourced clinical development from biotech and pharma companies should drive growth for large contract research organizations like Icon. We forecast Icon will reach mid-single-digit annual revenue growth in the latter years of our 10-year forecast period.

Headquartered in Ireland, the company benefits from a lower tax rate than its US peers, and we forecast a long-term tax rate of about 15%. We assume midcycle capital expenditures will be about 2% of sales.

We believe Icon warrants a no-moat rating. While the firm operates on a global scale and maintains expertise in clinical trials and regulatory processes, we no longer view its advantages as durable enough to maintain excess economic returns over a 10-year time horizon to support a narrow moat rating. Having the most impact, Icon’s 2021 acquisition of PRA Health Sciences appears to have been value-destructive to the firm’s returns on invested capital. There has also been increased competition among large CROs and questions surrounding Icon’s market share during its ongoing accounting investigation.

Icon significantly expanded its scale in 2021 through the $12 billion acquisition of PRA Health Sciences. The transaction combined two large CROs and broadened Icon’s geographic footprint and service offerings. Icon paid roughly a 30% premium for PRA Health and assumed a substantial amount of goodwill and intangible assets on its balance sheet. Management initially targeted cost synergies and operational efficiencies from the combination, but the company’s adjusted returns on invested capital have declined meaningfully since the transaction (below our WACC of 8.7% since 2021 and estimated to remain below until 2033). In our view, the size of the purchase price relative to the realized synergies suggests the acquisition has diluted economic returns rather than strengthened Icon’s competitive position. While the deal expanded Icon’s geographic footprint and offerings, we do not believe the benefits justify the capital invested.

Over the past couple of years, Icon’s business performance has reflected a more cyclical demand environment with rising cancellations. Following strong demand during the pandemic period, clinical development spending has moderated as biotech funding slowed and large pharmaceutical firms became more selective with trial initiations. In 2024, Icon reported 2% revenue growth with modest earnings expansion and entered 2025 with continued demand uncertainty amid soft biotech funding levels and customers delaying their clinical development decisions.

Recently, operational uncertainty has increased following an internal investigation into the company’s accounting practices in February 2026, which is related to Icon’s revenue recognition between 2023 and 2025. The probe, which could involve revenue overstatements of less than 2% in 2023-2024, prompted the company to withdraw its 2025 financial guidance and delay its financial reporting. The disclosure contributed to a 40% decline in the company’s share price and heightened investor concerns about governance and financial controls, plus there are multiple securities fraud class-action lawsuits filed against the firm.

Our low-single-digit sales forecast is driven less by the mechanical revenue correction and more by second-order effects, such as competitive pressure leading to potential market share loss during the investigation period (2023-25), slower bookings, reputational risks, and internal control concerns. If Icon faces market share pressure, it will need to offer discounts to win future business and accept lower-margin contracts, which would reduce growth over the next several years. Even modest market share slippage in the competitive CRO market can dampen the growth trajectory for several years, and that lower revenue base compounds over time.

Icon’s scale, capabilities, and established client relationships should allow the company to retain a share of industry demand within the CRO market. However, we do not expect Icon’s adjusted returns on invested capital to be consistently above its weighted average cost of capital over the long term, which reinforces our no-moat rating for Icon.

If biotech funding recovers and clinical trial starts increase, this could improve bookings growth, lower cancellations, and return to mid‑single‑digit revenue growth.

If Icon's accounting probe concludes with immaterial restatements and it rebounds with stronger near-term revenue growth, investor confidence could be restored.

As an Irish company, Icon benefits from a lower tax rate than many of its peers based in the United States.

Drawbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Icon's growth.

Icon could fail to innovate and keep an edge over regional and global CRO competitors, especially as data and analytics play an increasing role in clinical development.

Competitive pressure could force Icon to accept lower‑margin contracts to retain or win business, which could constrain growth.